1. Scrip
  2. >>R&D

Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

 
• By Sukaina Virji

The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?

Inchworms
Does Roche's failure indicate need for route change for IO in bladder cancer? • Source: Shutterstock

Roche's difficulties in confirming Tecentriq's efficacy in second line bladder cancer will likely have sent a shiver of unease through its competitors, rather than a cheer. (Also see "Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial" - Scrip, 10 May, 2017.)

Tecentriq (atezolizumab) is one of five similar products on or close to market for the same indication. Could this be a class effect? Or even more broadly concerning – might...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip